Literature DB >> 33195738

Does the natural product, honokiol, have value in the battle against osimertinib resistance?

Karin A Vallega1, Shi-Yong Sun1.   

Abstract

Entities:  

Keywords:  EGFR mutation; honokiol; lung cancer; natural products; osimertinib; resistance

Year:  2020        PMID： 33195738      PMCID： PMC7640904          DOI： 10.18632/oncoscience.517

Source DB:  PubMed          Journal:  Oncoscience        ISSN： 2331-4737


× No keyword cloud information.
  11 in total

Review 1.  Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.

Authors:  Ayesha Murtuza; Ajaz Bulbul; John Paul Shen; Parissa Keshavarzian; Brian D Woodward; Fernando J Lopez-Diaz; Scott M Lippman; Hatim Husain
Journal:  Cancer Res       Date:  2019-02-04       Impact factor: 12.701

Review 2.  Safety and Toxicology of Magnolol and Honokiol.

Authors:  Andrea Sarrica; Natalja Kirika; Margherita Romeo; Mario Salmona; Luisa Diomede
Journal:  Planta Med       Date:  2018-06-20       Impact factor: 3.352

Review 3.  Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets.

Authors:  Kishore Banik; Abhishek Manoj Ranaware; Vishwas Deshpande; Savita Pravin Nalawade; Ganesan Padmavathi; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Muthu K Shanmugam; Lu Fan; Frank Arfuso; Gautam Sethi; Ajaikumar B Kunnumakkara
Journal:  Pharmacol Res       Date:  2019-04-17       Impact factor: 7.658

4.  Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.

Authors:  Xianhuo Wang; Xingmei Duan; Guangli Yang; Xiaoyan Zhang; Linyu Deng; Hao Zheng; Chongyang Deng; Jiaolin Wen; Ning Wang; Cheng Peng; Xia Zhao; Yuquan Wei; Lijuan Chen
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 5.  Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

Authors:  Tri Le; David E Gerber
Journal:  Cancers (Basel)       Date:  2019-03-15       Impact factor: 6.639

6.  Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.

Authors:  Hongjing Zang; Guoqing Qian; Jack Arbiser; Taofeek K Owonikoko; Suresh S Ramalingam; Songqing Fan; Shi-Yong Sun
Journal:  Mol Oncol       Date:  2020-02-14       Impact factor: 6.603

7.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Authors:  Suresh S Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng-Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2019-11-21       Impact factor: 91.245

8.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

9.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

Review 10.  Osimertinib making a breakthrough in lung cancer targeted therapy.

Authors:  Haijun Zhang
Journal:  Onco Targets Ther       Date:  2016-09-06       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.